Bromelain / HO-1 Cancer Research Results

Bromelain — bromelain is a proteolytic enzyme complex derived mainly from pineapple stem, with lesser related fractions from fruit. It is best classified as a botanical protease mixture / natural product nutraceutical rather than a single defined small molecule. Standard abbreviations include bromelain and BML. Its functional identity is a cysteine-protease-rich mixture with anti-inflammatory, immunomodulatory, mucolytic, and context-dependent anticancer activity. In oncology, the most defensible interpretation is that bromelain is an experimental adjunct with preclinical antitumor and anti-metastatic signals, but without established mainstream systemic anticancer approval or definitive phase III evidence.

Primary mechanisms (ranked):

1. Proteolytic modulation of cell-surface and extracellular targets, including adhesion/invasion-associated proteins, contributing to reduced migration, metastatic competence, and tumor-supportive signaling.
2. Suppression of inflammatory survival signaling, especially NF-κB–COX-2 and related MAPK-linked pathways, lowering pro-survival and pro-tumor inflammatory tone.
3. Induction of tumor-cell death programs, including mitochondrial apoptosis and, in some models, ROS-linked autophagy/apoptosis coupling.
4. Immunomodulation, including effects on leukocyte/monocyte function and dendritic-cell maturation, with possible restoration of impaired anticancer immune activity in some contexts.
5. Mucolytic / stromal-disruptive activity when paired with acetylcysteine in mucinous tumors, which is mechanistically distinct from its broader nutraceutical use.
6. Bioenhancement / delivery support for selected co-administered agents, but this remains formulation- and context-dependent rather than a universal property.

Bioavailability / PK relevance: Oral bromelain shows limited but real absorption of intact enzymatically active material; circulating enzyme is partly bound by antiproteases such as α2-macroglobulin and α1-antichymotrypsin. This supports systemic biological plausibility, but exposure is constrained, heterogeneous, and not well standardized across products. As a protease mixture, batch composition and formulation materially affect PK relevance.

In-vitro vs systemic exposure relevance: Many anticancer in-vitro studies use bromelain concentrations that are difficult to map directly onto human systemic exposure because bromelain is a heterogeneous enzyme mixture rather than a single analyte. Therefore, direct translation of cell-culture dose levels to oral human dosing is weak. Mechanistic plausibility exists, but potency in vitro likely overstates predictable systemic anticancer exposure from standard oral supplements.

Clinical evidence status: Preclinical evidence is substantial. Human oncology evidence is limited and mostly adjunctive or exploratory, including small supportive studies on immune modulation or treatment side effects, plus early-phase mucinous-tumor work with BromAc rather than bromelain alone. No established standard-of-care systemic anticancer indication is supported at present.

Mechanistic relevance in cancer

P: 0–30 min

R: 30 min–3 hr

G: >3 hr